Status:
COMPLETED
Regulatory TYKERB® Tablets PMS
Lead Sponsor:
GlaxoSmithKline
Conditions:
Cancer
Eligibility:
All Genders
Brief Summary
Non-interventional, open-label, single group, multicentric post-marketing surveillance to monitor the safety and effectiveness of TYKERB® tablets administered in Korean patients according to the presc...
Detailed Description
Non-interventional, open-label, single group, multicentric post-marketing surveillance to monitor the safety and effectiveness of TYKERB® tablets administered in Korean patients according to the presc...
Eligibility Criteria
Inclusion
- All subjects must satisfy the following criteria at PMS entry according to MFDS PMS regulation:
- Subjects with indication in the locally approved prescribing information
- Subjects with no contraindication according to the prescribing information
Exclusion
Key Trial Info
Start Date :
January 1 2010
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 1 2014
Estimated Enrollment :
750 Patients enrolled
Trial Details
Trial ID
NCT00975988
Start Date
January 1 2010
End Date
July 1 2014
Last Update
October 27 2014
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
GSK Investigational Site
Seoul, South Korea, 110-744
2
GSK Investigational Site
Seoul, South Korea, 134-701